Basilea Pharmaceutica AG, invites you to participate in a conference call on Thursday, February 3rd, 2005 during which Dr. Anthony Man CEO will be joined by Mr. Ronald Scott CFO to provide an update on the company's activities and business outlook related to ceftobiprole (BAL5788), Basilea's first-in-class broad-spectrum anti-MRSA cephalosporin antibiotic following today's announcement of a collaboration with Johnson & Johnson's affiliate Cilag AG International.
